2 481

Cited 16 times in

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial

DC Field Value Language
dc.contributor.author김세규-
dc.contributor.author김세현-
dc.contributor.author김주항-
dc.contributor.author박무석-
dc.contributor.author손주혁-
dc.contributor.author신상준-
dc.contributor.author장준-
dc.contributor.author정민규-
dc.contributor.author정재헌-
dc.contributor.author조병철-
dc.contributor.author최혜진-
dc.date.accessioned2015-04-23T17:11:04Z-
dc.date.available2015-04-23T17:11:04Z-
dc.date.issued2010-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/101981-
dc.description.abstractBACKGROUND: Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure. PATIENTS AND METHODS: SCLC patients, who had relapsed at least 3 months after achieving objective response to irinotecan plus platinum chemotherapy, were eligible. Belotecan was administered at a dose of 0.5 mg/m(2)/day for 5 consecutive days every 3 weeks. RESULTS: Twenty-seven patients were enrolled in this study. Twenty-five patients were evaluated for response, and 27 patients were evaluated for toxicity and survival. The overall response rate was 22%. The median time to progression was 4.7 months (95% CI, 3.6-5.8 months), and the median overall survival was 13.1 months (95% CI, 10.4-15.8 months). The most frequent grade 3/4 toxicities were neutropenia (93%) and thrombocytopenia (48%). There was one treatment-related death due to pneumonia. CONCLUSION: Belotecan showed modest activity and manageable toxicities in relapsing SCLC patients in this study which was conducted in Asia. But further study in Caucasian patients is needed.-
dc.description.statementOfResponsibilityopen-
dc.format.extent77~81-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCamptothecin/administration & dosage-
dc.subject.MESHCamptothecin/adverse effects-
dc.subject.MESHCamptothecin/analogs & derivatives*-
dc.subject.MESHCamptothecin/therapeutic use-
dc.subject.MESHCarcinoma, Small Cell/drug therapy*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOrganoplatinum Compounds/administration & dosage-
dc.subject.MESHSalvage Therapy-
dc.subject.MESHTopoisomerase I Inhibitors/adverse effects-
dc.subject.MESHTopoisomerase I Inhibitors/therapeutic use*-
dc.titleBelotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJaeheon Jeong-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorJoo Hyuk Sohn-
dc.contributor.googleauthorHye Jin Choi-
dc.contributor.googleauthorSe Hyun Kim-
dc.contributor.googleauthorYoung Joo Lee-
dc.contributor.googleauthorMin Kyu Jung-
dc.contributor.googleauthorSang Joon Shin-
dc.contributor.googleauthorMoo-Suk Park-
dc.contributor.googleauthorSe Kyu Kim-
dc.contributor.googleauthorJoon Chang-
dc.contributor.googleauthorJoo Hang Kim-
dc.identifier.doi10.1016/j.lungcan.2010.01.006-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00602-
dc.contributor.localIdA00607-
dc.contributor.localIdA00945-
dc.contributor.localIdA01457-
dc.contributor.localIdA01995-
dc.contributor.localIdA02105-
dc.contributor.localIdA03472-
dc.contributor.localIdA03606-
dc.contributor.localIdA03714-
dc.contributor.localIdA03822-
dc.contributor.localIdA04219-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid20138389-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500210000085-
dc.subject.keywordBelotecan-
dc.subject.keywordSCLC-
dc.subject.keywordTopoisomerase I inhibitor-
dc.contributor.alternativeNameKim, Se Kyu-
dc.contributor.alternativeNameKim, Se Hyun-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNamePark, Moo Suk-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameShin, Sang Joon-
dc.contributor.alternativeNameChang, Joon-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.alternativeNameJung, Jae Hun-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.affiliatedAuthorKim, Se Kyu-
dc.contributor.affiliatedAuthorKim, Se Hyun-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorPark, Moo Suk-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorShin, Sang Joon-
dc.contributor.affiliatedAuthorChang, Joon-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorJung, Jae Hun-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorChoi, Hye Jin-
dc.citation.volume70-
dc.citation.number1-
dc.citation.startPage77-
dc.citation.endPage81-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.70(1) : 77-81, 2010-
dc.identifier.rimsid52633-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.